CDKN2A and renal cell carcinoma: Moreover, the genomic alteration of CDKN2A was also significantly associated with shorter DSS (P < 0.0001, HR = 7.415), PFS (P < 0.0001, HR = 6.441), DFS (P < 0.0001, HR = 5.902), and OS (P < 0.0001, HR = 4.837) in 3,563 patients with RCC from the Western cohort (Figure 3B).